Sermonix Pharmaceuticals, Inc.

Lasofoxifene Shows Promise in Early Breast Cancer Treatment, I-SPY 2 Trial Data Reveal

- Lasofoxifene demonstrates a strong tolerability profile and promising Ki67 suppression in a Phase 2 study, supporting further exploration in the neoadjuvant setting. - In premenopausal patients, early Ki67 suppression was observed without ovarian function suppression, suggesting a unique benefit for younger women with breast cancer. - The I-SPY 2 EOP study highlights lasofoxifene's significant activity in molecularly selected patients, showing potential in tumors predicted to have limited chemotherapy benefit. - Adverse events were mild, with hot flushes, constipation, fatigue, and nausea being the most common, indicating a favorable safety profile for lasofoxifene.